A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:November 7, 2017
End Date:December 22, 2025
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab
administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with
active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

This study consists of 3 phases: Screening Phase (up to 35 days), an Active Monitoring Phase
or a Treatment Phase of 39 cycles or 36 months (whichever occurs first), and a Follow-up
Phase which will continue until death, lost to follow-up, consent withdrawal, or study end
(approximately 8 years after the first participant is randomized), whichever occurs first.
Active monitoring cycles and treatment cycles are 4 weeks in length. For all participants,
disease evaluations will be performed every 12 weeks until confirmed progressive disease
(PD). After PD, survival is to be followed at least every 6 months, until the end of the
study. Participants will undergo tumor assessments, pharmacokinetics, biomarkers and safety
evaluations (adverse events, laboratory tests, vital sign measurements, physical
examinations, Eastern Cooperative Oncology Group [ECOG] performance status) over the time.

Inclusion Criteria:

- Diagnosis of high risk smoldering multiple myeloma (SMM) (per International Myeloma
Working Group [IMWG] criteria) for less than or equal to (<=) 5 years with measurable
disease at the time of randomization, defined as serum M protein greater than or equal
to (>=) 10 gram per liter (g/L) or urine M protein >= 200 milligram per 24 hours
(mg/24 hours) or involved serum free light chain (FLC) >=100 milligram per liter
(mg/L) and abnormal serum FLC ratio

- Clonal bone marrow plasma cells (BMPCs) >= 10 percentage (%); and at least 1 of the
following risk factors; Serum M protein >= 30 g/L, immunoglobulin (Ig)A SMM,
immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes (only IgA, IgM,
and IgG should be considered in determination for immunoparesis; IgD and IgE are not
considered in this assessment), serum involved: uninvolved FLC ratio >= 8 and less
than (<) 100, or clonal BMPCs greater than (>) 50% to <60% with measurable disease

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Women of childbearing potential must commit to either abstain continuously from
heterosexual sexual intercourse or to use highly effective method of contraception

- A woman of childbearing potential must have a negative serum or urine pregnancy test
at screening within 14 days prior to randomization

- During the study and for 3 months after receiving the last dose of daratumumab, a
woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
reproduction

Exclusion Criteria:

- Multiple myeloma (MM), requiring treatment, defined by any of the following:

1. Bone lesions (1 or more osteolytic lesions on low-dose whole body computed
tomography [LDCT], positron-emission tomography with computed tomography [PET-CT]
or CT). Participants who have benign/post-traumatic bone lesions visible on
screening images as well as previous imaging, may be considered for inclusion.
Details (diagnosis, location, duration) on benign/post-traumatic pre-existing
bone lesions that can be seen on the screening images (example [eg.], old
fractures) and were also present on previous imaging are to be reported in the
case report form (CRF)

2. Hypercalcemia (serum calcium greater than [>]0.25 millimoles per liter [mmol/L]
[>1 milligram per deciliter {mg/dL}] higher than upper limit of normal [ULN] or
>2.75 mmol/L [>11 mg/dL]). Participants who have clinically stable hypercalcemia
attributable to a disease other than multiple myeloma (eg, hyperparathyroidism)
may be considered for inclusion after a case by case review by the medical
monitor

3. Renal insufficiency, preferably determined by creatinine clearance less than
(<)40 milliliter per minute (mL/min) measured or estimated using the Modification
of Diet in Renal Disease (MDRD), or serum creatinine >177 micromole per liter
(μmol/L). Participants who have clinically stable renal insufficiency
attributable to a disease other than multiple myeloma (eg, glomerulonephritis)
may be considered for inclusion after a case by case review by the medical
monitor

4. Anemia, defined as hemoglobin <10 gram per deciliter (g/dL) or >2 g/dL below
lower limit of normal or both; transfusion support or concurrent treatment with
erythropoietin stimulating agents is not permitted. Participants who have
clinically stable anemia attributable to a disease other than multiple myeloma
(eg, thalassemia, vitamin B12 deficiency, iron deficiency) may be considered for
inclusion after a case by case review by the medical monitor

5. Clonal BMPC percentage >=60%

6. Serum FLC ratio (involved:uninvolved) >=100 (the involved FLC must be >=100 mg/L)

7. More than 1 focal lesion >=5 millimeter (mm) in diameter by magnetic resonance
imaging (MRI)

- Primary systemic amyloid light-chain (AL) (immunoglobulin light chain) amyloidosis

- Exposure to any of the following:

1. Prior exposure to daratumumab or prior exposure to other anti-Cluster of
Differentiation 38 (anti-CD38) therapies

2. Prior exposure to approved or investigational treatments for SMM or MM (including
but not limited to conventional chemotherapies, immunomodulatory agent [IMiDs],
or proteasome inhibitor [PIs]). Stable standard dosing of bisphosphonate and
denosumab as indicated for osteoporosis is acceptable

3. Exposure to investigational drug (including investigational vaccines) or invasive
investigational medical device for any indication within 4 weeks or 5 half-lives,
whichever is longer, before Cycle 1, Day 1

4. Ongoing treatment with corticosteroids with a dose >10 milligram (mg) prednisone
or equivalent per day at the time of randomization; or >280 mg cumulative
prednisone dose or equivalent for any 4-week period in the year prior to
randomization

5. Ongoing treatment with other monoclonal antibodies (eg, infliximab, rituximab),
immunomodulators (eg, abatacept, methotrexate, azathioprine, cyclosporine) or
other treatments that are likely to interfere with the study procedures or
results

- Received treatment (chemotherapy, surgery, et cetera [etc]) for a malignancy (other
than SMM) within 3 years before the date of randomization (exceptions are squamous and
basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other
non-invasive lesion), which is considered cured with minimal risk of recurrence within
3 years

- Medical or psychiatric condition or disease (for example, active systemic disease
[including presence of auto-antibodies], uncontrolled diabetes) that is likely to
interfere with the study procedures or results, or that in the opinion of the
investigator, would constitute a hazard for participating in this study

- Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal
antibodies, hyaluronidase, or other human proteins, or their excipients, or known
sensitivity to mammalian-derived products (including dairy allergy)
We found this trial at
29
sites
1640 Avenida Pueyrredón
Buenos Aires, C1118
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Albany, New York 12206
?
mi
from
Albany, NY
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Austin, Texas 78731
?
mi
from
Austin, TX
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1021 Morehead Medical Drive
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75216
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Metairie, Louisiana 70006
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
6900 North Pecos Road
North Las Vegas, Nevada 89086
?
mi
from
North Las Vegas, NV
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
3303 Southwest Bond Avenue
Portland, Oregon 97239
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Tyler, Texas 75702
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Whittier, California 90603
?
mi
from
Whittier, CA
Click here to add this to my saved trials